GLP-1 Therapy Linked to Sensory Disturbances in Type 2 Diabetes
Long-term use of glucagon-like peptide 1 receptor agonists is linked to a higher risk of disturbances in smell and…
-
-
Researchers Find Which GLP-1 Treatment Delivers the Greatest Weight Loss
A recent study from the University of Georgia found that the weight-loss drug tirzepatide is more effective than semaglutide…
-
GLP-1 Receptor Agonists May Promote Bone Health Alongside Weight Loss in Type 2 Diabetes
People living with type 2 diabetes face a hidden danger because the disease weakens their bones. This condition alters…
-
GLP-1 Receptor Agonists Reduce Major Kidney Events and Mortality in Transplant Recipients With Type 2 Diabetes
A systematic review of 7,012 kidney transplant recipients with type 2 diabetes shows that specific therapy offers survival benefits….
-
Understanding Why Patients Respond Differently to GLP-1 Drugs
GLP-1 receptor agonists offer a major advancement for managing obesity and type 2 diabetes. Medications like semaglutide and tirzepatide…
-
Wegovy for More Than Weight Loss: Seven Potential Health Advantages
Semaglutide, best known by its brand name Wegovy, has completely changed how we treat obesity. With an FDA-approved daily…
-
GLP-1 Receptor Agonists and Bile Acid Malabsorption: Emerging Evidence and Mechanisms
Bile acid malabsorption affects about 1% of the general population. This condition causes chronic and socially difficult symptoms. Patients…
-
Protecting Muscle Mass While Using GLP-1 Medications: A Nutrition Guide
New medications for weight loss have changed how we treat obesity and type 2 diabetes. These drugs, known as…
-
GLP-1 Drug Users Show Reduced Risk of Disease After Weight Loss, Study Reports
Obesity currently affects more than 40 per cent of adults. This condition drives high rates of heart disease and…
-
Eli Lilly’s Retatrutide Achieves Significant Weight Loss in Clinical Trial
The phase 3 trial findings for Eli Lilly’s experimental treatment for obesity, retatrutide, were declared as successful. According to…
